

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation		DHS/CHB	Supervisor: Lisa Guli x5607 Epidemiologist: Jennifer Plaster x5664
Program Purpose	Prevent and control the spread of communicable diseases		
Program Information	<p>The Public Health Division’s Disease Surveillance and Investigation (DSI) program is legally mandated by the <i>Code of Virginia</i> to monitor and investigate specific diseases or toxic exposures reported to have occurred in the community, with a primary goal of preventing and controlling additional cases that may lead to an outbreak.</p> <p>Hospitals, laboratories, and health care providers in Arlington are required to report nearly 80 suspected or confirmed cases of diseases or toxic exposures to the Public Health Division (PHD), as outlined on the Virginia Reportable Disease List.</p> <p>Reportable Disease Investigation</p> <p>There are two categories within the Virginia Reportable Disease List.</p> <ul style="list-style-type: none"> • Thirty conditions are considered <i>rapidly reportable diseases</i> and have a strict requirement for immediate reporting to PHD because the diseases listed may spread very quickly from person-to-person or cause severe illness or death in those infected. DSI staff must start the case investigation immediately upon receipt of a report of a rapidly reportable disease. <ul style="list-style-type: none"> ○ Examples of rapidly reportable diseases include measles, hepatitis A, Ebola, primary and secondary syphilis, and suspected agents of bioterrorism, such as anthrax. Clusters or suspected outbreaks of any illness, not only those on the Virginia Reportable Disease List, are also considered <i>rapidly reportable</i>. ○ Mpox is considered a rapidly reportable disease, as an unusual occurrence of disease of public health concern. • The remaining conditions listed are required to be reported within three days. <ul style="list-style-type: none"> ○ Examples include salmonellosis, campylobacteriosis, chickenpox, and giardiasis. ○ COVID-19 is no longer a rapidly reportable disease, as of January 2023. <p>Public health investigation of a reportable condition works to:</p> <ul style="list-style-type: none"> • Confirm the diagnosis and treatment by a medical provider • Assess the patient’s possible exposures and location before illness • Determine additional cases or persons exposed who may need additional follow-up for treatment for the same condition or preventive medical treatment, known as post-exposure prophylaxis (PEP) • Recommend specific infection control measures that would subsequently reduce the opportunity for the same illness to develop in friends, family and the community of the case <p>Disease investigations also include potential rabies exposure investigations. Potential rabies exposures include all bites to humans by animals that can potentially carry rabies (mammals), regardless of perceived risk. Rabies is</p>		

transmitted through any bite, scratch, or other circumstance where saliva or central nervous system tissue from a rabid animal enters an open, fresh wound or comes in contact with a mucous membrane (eye, mouth, or nose). The highest risk for rabies in Virginia is from bats and carnivorous mammals such as raccoons, skunks, and foxes.

Outbreak Investigations

Community members, congregate facilities, and medical providers report when they believe there is an unusual increase in cases of similar illness. These *illness clusters* are investigated and monitored by DSI staff to determine if there is any transmission between cases or if there has been a common exposure, whether biological or chemical. If so, DSI staff will define the disease cluster as an outbreak and conduct a full investigation and actively monitor until additional cases have ceased to occur.

An outbreak is defined as the occurrence of more cases of illness than expected, with similar symptoms, a common exposure, and illness onset at or around the same time. DSI staff investigate to:

1. Determine what agent is causing the symptoms and illness
2. Identify a common exposure
3. Make recommendations to control and/or prevent further spread of illness

Investigations of rapidly reportable diseases and outbreaks receive priority attention. Depending on the scope and duration of the outbreak, this may result in the need to delay the investigation of some conditions on the reportable disease list that are not communicable or cause less severe illness. Some examples of investigations that may be delayed include chronic hepatitis B, chronic hepatitis C, and Lyme disease.

COVID-19: The Federal government public health emergency declaration for COVID-19 ended on May 11, 2023. County emergency and containment response efforts to prevent and control transmission of COVID-19 continued into FY 2023, closing out toward the end of the fiscal year. Responsibility for follow up on reports of outbreaks and unusual cases of COVID-19 transitioned to the CD Team in June 2023.

Mpox Virus Outbreak 2022: In May 2022, public health authorities in several countries, including the United States, detected an uptick of cases in mpox virus occurring primarily in populations of men who have sex with men (MSM). While mpox was originally identified in 1958, large numbers of cases and sustained ongoing transmission across multiple countries did not occur outside of central and west Africa until the 2022 outbreak. Arlington’s CD team first responded to the US outbreak in May 2022 and continued its own response to the mpox virus outbreak, primarily through the first quarter of FY 2023. The CD team led the response through initial provision of on-site testing, vaccination of high-risk close contacts, and subsequently through ongoing disease surveillance, case investigation and contact tracing. This public health emergency continued into FY 2023 with the

FY 2023 PERFORMANCE PLAN

majority of cases reported in the first quarter. During FY 2023, there were 59 cases of mpox reported in Arlington County. Arlington County had the second highest case-rate for mpox among Virginia health districts in FY 2023, behind Alexandria City.

Community Partners
Animal Welfare League of Arlington (AWLA), Virginia Hospital Center, the INOVA systems, Division of Consolidated Laboratories, Virginia Department of Health (VDH), other Northern Virginia health departments, mandated reporters.

Service Delivery Model

- Services were delivered using a hybrid model (in-person and remote) in FY 2023.
- In FY 2024, services will continue to be delivered using a hybrid model of in-person and remote services, with team members present in the office for a minimum of two days each week.

PM1: How much did we do?

Staff

Total 6 FTEs:

- 1 FTE Supervisor
- 2 FTE Program Epidemiologists
- 2 FTE Public Health Nurses (40% of 5 FTEs)
- 1 FTE Disease Intervention Specialist (DIS)

Total Contract Staff

- 1 FTE VDH Contracted Disease Intervention Specialist (DIS)

Customers and Service Data		FY 2020	FY 2021	FY 2022	FY 2023
	Disease Investigations	1,292	1,213	1,359	1,475
	Confirmed, Probable, and Suspect Cases	636	377	542	629
	Clusters Reported	25	2	13	47
	Confirmed Outbreaks	10	2	12	38

Data excludes COVID-related investigations, cases, clusters, and outbreaks.

PM2: How well did we do it?

2.1 Initiation of investigation within required VDH timeframes

2.2 Outbreak investigations contained all required elements

PM3: Is anyone better off?

3.1 Control measures recommended according to VDH criteria and timeframe



3.2 Completion of prophylaxis to prevent rabies as recommended

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation

Measure 1 Disease Investigations

Data



Data Summary

- In FY 2023, 1,475 disease investigations were conducted.
- Data collected through the Virginia Electronic Disease Surveillance System (VEDSS).
- The racial equity analysis does not include COVID-19 investigations, disease reports that were deemed "not a case", or bite cases reported by AWLA.
- In FY 2023, 12% (race) and 24% (ethnicity) of disease investigations have unknown client race/ethnicity and are not included in the above Racial Equity Analysis chart.

What is the story behind the data?

- In FY 2023, the number of investigations was higher than recent fiscal years, and more similar to fiscal year data before the COVID-19 pandemic. This increase may be due to residents returning to school, worksites and recreation in the community at pre-pandemic levels.
- Investigations were conducted for non-COVID reportable illnesses and potential rabies exposures. While data on most reportable conditions are presented with client race and ethnicity, this information is incomplete for potential rabies exposures in FY 2023. In FY 2023, changes were made in the second half of the FY to begin collecting race and ethnicity data from bite reports and Virginia health care facilities.

FY 2023 PERFORMANCE PLAN

- Data missing on race and/or ethnicity are typically due to incomplete data for bite reports, as well as some investigations (Hepatitis B, C and Lyme disease) not requiring client contact for closing the investigation and determining a case status, with no race/ethnicity reported on lab result.
- Non-TB communicable diseases are investigated when clients are ill or recently recovered, though possibly still infectious. Therefore, client services are provided over the phone, with limited and situation-specific need to interact with a client in-person, even when staff are present in the office. This is an unchanged service delivery model; remote/hybrid work has not significantly impacted services to our clients.


Recommendations	Target Dates
<ul style="list-style-type: none"> • Continue to investigate reportable diseases among Arlington residents, according to state and local guidance. • Continue conversations with AWLA in first quarter of FY 2024 how to best capture and aggregate data on race and ethnicity reported to them by providers. 	<ul style="list-style-type: none"> • On-going • On-going
Forecast	
<ul style="list-style-type: none"> • In FY 2024, it is expected that the number of investigations will remain around 1,475. 	

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation

Measure 1 Confirmed Outbreaks

Data



Data Summary

- In FY 2023, there were 38 confirmed non-COVID outbreaks.
- Data do not include COVID or mpox outbreaks.
- Data collected by VDH in the Virginia Outbreak Surveillance System (VOSS).

What is the story behind the data?

- In FY 2023, the number of outbreaks reported and investigated was higher than in the previous three years, when more strict community infection control measures were in place for COVID-19. In FY 2023, with fewer restrictions in place to limit COVID, other disease outbreaks increased.
- The non-COVID outbreaks reported in FY 2023 were respiratory diseases, dermatological, or gastrointestinal illnesses that occurred in daycare, school, or long-term care settings.
- The program has continued to conduct site visits for facilities experiencing outbreaks. During site visits staff can observe where there is a need for improved infection control, provide in-person education and resources (including for specimen collection, when appropriate), and build relationships with partners in the community that serve special or vulnerable populations.

Recommendations

- Continue to investigate reported outbreaks and recommend infection control measures upon notification.

Target Dates

- On-going

Forecast


- In FY 2024, the status of outbreak reports is unpredictable.

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation

Measure 2.1 Initiation of investigation within required VDH timeframes

Data



Data Summary

- In FY 2023, 99% of case investigations (280 of 282) were initiated within VDH timeframes, exceeding the goal of 95%. A sample of case investigations are included in this measure.
- Data collected through the Virginia Electronic Disease Surveillance System (VEDSS).
- These numbers do not include chronic hepatitis B, chronic hepatitis C, Lyme disease, late syphilis, HIV, potential rabies exposures, or COVID-19.
- While active tuberculosis is a rapidly reportable disease in Virginia, it is excluded from this measure. Active TB investigations are reported in the Tuberculosis performance plan.

What is the story behind the data?

- Timeframes for investigating all diseases are within three days unless they are rapidly reportable and investigated immediately.
- Outbreaks involving rapidly reportable diseases are followed in real time, regardless of the date of arrival, to ensure immediate initiation of an investigation.
- The timeframes are based on the agent causing the illness, the time it takes from exposure to develop symptoms, and measures needed to control disease spread.
 - In FY 2023, of the 282 sample investigations, 58 were rapidly reportable disease investigations.
 - All 58 rapidly reportable diseases investigations were initiated within the VDH timeframe.
- Prompt disease investigation leads to early identification of sources and initiation of control measures, limiting or preventing further spread in the community.
- Disease reports are received in a variety of methods (electronic reporting, phone, fax, mail). Hard copies of reports received by fax or mail are manually entered into VEDSS.
- All investigations are documented in the local database and staff are automatically notified when cases are assigned.

FY 2023 PERFORMANCE PLAN

- Currently VEDSS uses a sampling scheme to determine which cases are included in the report on timeliness. The report is continually being improved, resulting in a larger sample of cases this year.
- Best practices for investigating cases are routinely shared in team meetings.

Recommendations

Target Dates

- Continue to monitor and identify patterns that may indicate a larger cluster or outbreak in the community.


- On-going

Forecast

- In FY 2024, the initiation of case investigations within required VDH timeframes will remain about 99%.

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation



Data Summary

- This is a new indicator as of FY 2022, replacing the previous indicator measuring if reports were sent in the mandated reported timeframe. Currently, VDH does not have a specific expected timeline for outbreak closures.
- In FY 2023, the CD team submitted all outbreak reports to the Virginia Outbreak Surveillance System (VOSS) with all minimum elements for outbreak closure, as outlined by VDH.
- Data collected by VDH in VOSS.

What is the story behind the data?

- The required elements of an outbreak investigation report tell the story of the outbreak – who was affected, where and how, and assist the CD team and VDH by providing a summary of lessons learned and best practices to implement for the future outbreaks.
- The required elements include details such as the duration of the outbreak, infection control measures recommended and implemented, and the total number of cases, hospitalizations and deaths associated with the outbreak.

Recommendations	Target Dates
<ul style="list-style-type: none"> • Continue to monitor and identify patterns or feedback from VDH that may indicate need for improved documentation 	<ul style="list-style-type: none"> • On-going

Forecast


- In FY 2024, the status of outbreak reports will be about 100%.

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation

Measure 3.1 Individual Disease Control measures recommended according to VDH criteria and timeframe

Data



Data Summary

- VDH tracks initiation of control measures as indicated for 10 diseases: botulism, shiga toxin-producing E. coli, hepatitis A, measles, meningococcal disease, tularemia, salmonellosis, typhoid fever, paratyphoid fever, and shigellosis.
- In FY 2021, this measure was updated to include all DSI investigations, excluding COVID-19. Previous years only report on the 10 diseases listed above.
- In FY 2023, 96% (357 of 371) of clients received recommendations for control measures according to VDH guidelines and within the appropriate timeframes.
- Data collected through the Virginia Electronic Disease Surveillance System (VEDSS) and the DSI local database.

What is the story behind the data?

- Disease specific control measures are client education and guidance, which, when implemented are intended to interrupt ongoing transmission of the disease.
- Control measures include actions such as handwashing, covering coughs/sneezes, staying home when sick, environmental cleaning, physical distancing, taking medications as advised and post-exposure prophylaxis (medications and vaccines to prevent infection after exposure) for exposed contacts.
- Giving control measures according to the VDH guidelines is dependent on reaching the client and documenting that control measures were given. All staff are reminded to consistently and appropriately document control measures. No patterns were noted on those cases without documented control measures.

Recommendations

- Continue to report on all investigations and look for and address patterns.

Target Dates

- On-going

Forecast


- In FY 2024, control measures recommended per guidelines will remain about 96%.

FY 2023 PERFORMANCE PLAN

Disease Surveillance and Investigation

Measure 3.2 Completion of prophylaxis to prevent rabies as recommended

Data



Data Summary

- In FY 2023, 56% of clients completed prophylaxis to prevent rabies as recommended.
- Data is from the Potential Rabies Exposure Database.

What is the story behind the data?

- Post Exposure Prophylaxis (PEP) is recommended to prevent human rabies in those with suspected or confirmed exposure. A suspected exposure is when a person is bitten by an animal (domestic or wild) that cannot be *tested or observed* for rabies; it is assumed to be rabid, and PEP is recommended.
- All potential rabies exposures, for which the animal’s health cannot be assessed, receive calls and letters according to protocol, explaining the risk and Public Health recommendations.
- Some bitten clients refuse to report a known domestic animal’s whereabouts, for fear that AWLA will take it away. This is considered a “suspected exposure” and PEP is recommended, in accordance with VDH guidance; a client in this situation will often refuse PEP, as they feel they are not at risk for rabies.
- In FY 2023, the hospitals increased reporting of all animal bites.
- Once an exposed person develops symptoms, there is no effective treatment, and the disease is fatal. However, if PEP is given before symptoms develop, rabies is prevented.
- Staff continue to discuss challenges and strategies to overcome barriers and engage clients about accepting PEP recommendations.
- Ongoing quality assurance of database assures compliance with standard procedures.

Recommendations

- Continue to counsel persons with suspected exposures on severity of rabies virus and the importance of early intervention.

Target Dates

- On-going

FY 2023 PERFORMANCE PLAN

<ul style="list-style-type: none">Continue to follow VDH guidance and comply with documentation standards for persons who do not complete treatment as recommended.	<ul style="list-style-type: none">On-going
Forecast	
<ul style="list-style-type: none">In FY 2024, the completion of prophylaxis to prevent rabies as recommended will remain around 65%.	